July 12, 2024

The Expedited Diagnosis And Treatment Of Cholangiocarcinoma Is Driven By Increasing Prevalence Of Risk Factors

Cholangiocarcinoma, also known as bile duct cancer, is a rare cancer that forms in the bile duct. The bile duct is the tube that carries bile from the liver to the small intestine. Bile helps with digestion by helping to break down fats. Cholangiocarcinoma forms either inside or outside of the liver in the bile duct. The growth of this rare cancer can cause the bile duct to narrow and block the flow of bile. Some symptoms associated with this blockage are jaundice, abdominal pain, and itchy skin. Cholangiocarcinoma is typically treated by surgical resection of the tumor. Other treatment options are chemotherapy, radiation therapy, and liver transplantation in some cases. The development of advanced diagnosis and treatment options for cholangiocarcinoma is crucial due to its low survival rates.

The global Cholangiocarcinoma Market is estimated to be valued at US$ 7,275.7 Mn in 2024 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends: One of the key trends driving the growth of the cholangiocarcinoma market is the increasing risk factors associated with the disease such as primary sclerosing cholangitis (PSC) and liver fluke infections. PSC affects the bile ducts in the liver and increases the risk of developing cholangiocarcinoma by 30-40 times. Liver fluke infections caused by parasites such as Opisthorchis viverrini and Clonorchis sinensis have also been linked to increasing cholangiocarcinoma cases in Southeast Asia and East Asia. According to global burden of disease data, infection with the parasite O. viverrini causes over 900,000 cases of cholangiocarcinoma worldwide. Therefore, the rising prevalence of risk factors like PSC and parasitic infections is expected to upsurge the cases of cholangiocarcinoma, fueling the market growth over the forecast period.

Porter’s Analysis
Threat of new entrants: Low barriers to entry as the market is well established. However, developing novel treatment requires significant investment.

Bargaining power of buyers: Buyers have moderate bargaining power as alternative treatment options are limited.

Bargaining power of suppliers: Suppliers have high bargaining power as key players dominate the market. Suppliers may face reimbursement issues and price control by regulatory authorities.

Threat of new substitutes: Low threat as no major substitute exists for cholangiocarcinoma treatment.

Competitive rivalry: High competition among existing major players to gain more market share through new product launches and innovative therapies.

Key Takeaways
The global cholangiocarcinoma market is expected to witness high growth.

Regional analysis: Asia Pacific is projected to be the fastest growing market for cholangiocarcinoma owing to large patient population and improving healthcare infrastructure in China and India. Rising awareness among patients about early diagnosis and treatment is further augmenting the market growth in Asia Pacific.

Key players: Key players operating in the cholangiocarcinoma market are Johnson & Johnson Services, Inc., Cooper Companies Inc., Lifecell Corporation (Allergan Plc), W. L. Gore & Associates, Inc., Maquet Holding B.V. & Co. KG, Becton, Dickinson and Company, Medtronic Plc, Cook Medical Inc., Baxter International Inc., and B. Braun Melsungen AG. These players are adopting strategies such as acquisitions, partnerships, and new product launches to retain their market share.


  1. Source: Coherent Market Insights, Public sources, Desk research

2. We have leveraged AI tools to mine information and compile it